Cargando…
Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery
In 2001, a group of European academic surgeons created the Enhanced Recovery After Surgery (ERAS) study group and established the first official ERAS protocol. One of the most significant challenges during ERAS implementation is variability of drugs used throughout the perioperative period. Pharmaco...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6666379/ https://www.ncbi.nlm.nih.gov/pubmed/31440074 http://dx.doi.org/10.2147/PGPM.S198224 |
_version_ | 1783439981170130944 |
---|---|
author | Awad, Hamdy Ahmed, Ahmed Urman, Richard D Stoicea, Nicoleta Bergese, Sergio D |
author_facet | Awad, Hamdy Ahmed, Ahmed Urman, Richard D Stoicea, Nicoleta Bergese, Sergio D |
author_sort | Awad, Hamdy |
collection | PubMed |
description | In 2001, a group of European academic surgeons created the Enhanced Recovery After Surgery (ERAS) study group and established the first official ERAS protocol. One of the most significant challenges during ERAS implementation is variability of drugs used throughout the perioperative period. Pharmacogenomic testing (blood or saliva) results (obtained within approximately 48 hrs) provide guidelines on how to prescribe the optimal drug with the optimal dosage to each patient based on an individual’s unique genetic profile. Pharmacogenomic testing of various methods of multimodal analgesia is an essential element of ERAS protocols spanning the entire perioperative period to ultimately optimize postoperative pain control. The key goal for anesthetic management in ERAS protocols is to facilitate rapid emergence by using the shortest acting agents available, thus accelerating recovery and reducing length of stay, hospital expenses, and postoperative complications. Postoperative nausea and vomiting (PONV) is an additional challenge that should be overcome to ensure an enhanced recovery and shorter length of stay with the use of antiemetics. Postoperative ileus (POI) can result in longer hospital stay with increasing susceptibility to associated morbidities along with an increase in associated hospitalization costs. Genetics-guided pharmacotherapy and its impact on clinical outcomes should be thoroughly studied for better understanding and managing drug administration in the settings of ERAS. |
format | Online Article Text |
id | pubmed-6666379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66663792019-08-22 Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery Awad, Hamdy Ahmed, Ahmed Urman, Richard D Stoicea, Nicoleta Bergese, Sergio D Pharmgenomics Pers Med Review In 2001, a group of European academic surgeons created the Enhanced Recovery After Surgery (ERAS) study group and established the first official ERAS protocol. One of the most significant challenges during ERAS implementation is variability of drugs used throughout the perioperative period. Pharmacogenomic testing (blood or saliva) results (obtained within approximately 48 hrs) provide guidelines on how to prescribe the optimal drug with the optimal dosage to each patient based on an individual’s unique genetic profile. Pharmacogenomic testing of various methods of multimodal analgesia is an essential element of ERAS protocols spanning the entire perioperative period to ultimately optimize postoperative pain control. The key goal for anesthetic management in ERAS protocols is to facilitate rapid emergence by using the shortest acting agents available, thus accelerating recovery and reducing length of stay, hospital expenses, and postoperative complications. Postoperative nausea and vomiting (PONV) is an additional challenge that should be overcome to ensure an enhanced recovery and shorter length of stay with the use of antiemetics. Postoperative ileus (POI) can result in longer hospital stay with increasing susceptibility to associated morbidities along with an increase in associated hospitalization costs. Genetics-guided pharmacotherapy and its impact on clinical outcomes should be thoroughly studied for better understanding and managing drug administration in the settings of ERAS. Dove 2019-07-26 /pmc/articles/PMC6666379/ /pubmed/31440074 http://dx.doi.org/10.2147/PGPM.S198224 Text en © 2019 Awad et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Awad, Hamdy Ahmed, Ahmed Urman, Richard D Stoicea, Nicoleta Bergese, Sergio D Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery |
title | Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery |
title_full | Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery |
title_fullStr | Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery |
title_full_unstemmed | Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery |
title_short | Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery |
title_sort | potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6666379/ https://www.ncbi.nlm.nih.gov/pubmed/31440074 http://dx.doi.org/10.2147/PGPM.S198224 |
work_keys_str_mv | AT awadhamdy potentialroleofpharmacogenomicstestinginthesettingofenhancedrecoverypathwaysaftersurgery AT ahmedahmed potentialroleofpharmacogenomicstestinginthesettingofenhancedrecoverypathwaysaftersurgery AT urmanrichardd potentialroleofpharmacogenomicstestinginthesettingofenhancedrecoverypathwaysaftersurgery AT stoiceanicoleta potentialroleofpharmacogenomicstestinginthesettingofenhancedrecoverypathwaysaftersurgery AT bergesesergiod potentialroleofpharmacogenomicstestinginthesettingofenhancedrecoverypathwaysaftersurgery |